跳至主要内容
临床试验/ACTRN12619001554156
ACTRN12619001554156招募中1 期

A study to evaluate topical ABI-1968 cervical tissue penetration after multiple weekly topical ABI-1968 administration intravaginally in subjects prior to hysterectomy performed for benign indications.

Antiva Bioscience, Inc.0 个研究点目标入组 15 人开始时间: 2019年11月12日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
30 Years 至 55 Years(—)
性别
Female

入选标准

  • 1. Women between the ages of 30 and 55 years, who are premenopausal, with an intact uterus.
  • 2. Generally, in good health with no clinically significant pulmonary, cardiac, gastroenterologic,
  • neurologic, renal, musculoskeletal, rheumatologic, metabolic, neoplastic, or
  • endocrine disease.
  • 3. Scheduled for a hysterectomy for benign indications (e.g. fibroids, dysfunctional uterine
  • bleeding, urinary incontinence, pelvic pain etc).
  • 4. Agree to abstain from activities such as sexual intercourse, vaginal douching or insertion of
  • any vaginal products other than the study drug for at least 48 hours after each dose and to
  • minimize partner exposure to Topical ABI-1968 Gel during study participation.
  • 5. Able and willing to return to the clinic for all study procedures.
  • 6. Able and willing to provide informed consent.

排除标准

  • 1. Women who are pregnant
  • 2. Women who are post-menopausal
  • 3. History of cancer, except basal cell or squamous cell carcinoma of the skin.
  • 4. Have a diagnosis of a gynecological cancer or suspicion of cancer that leads to the
  • hysterectomy
  • 5. History of abnormal cervical cytology within the past 12 months
  • 6. History of excisional (e.g. LEEP, LLETZ) or ablative (e.g. cryo- or electrocautery, laser)
  • treatment to the cervix
  • 7. History of genital herpes with greater than 3 outbreaks per year, or active non-HPV vaginal infection.
  • 8. Have an active pelvic infection (positive urine screen for gonorrhea or chlamydial infection,
  • positive bedside testing criteria for bacterial vaginosis, candida vaginitis or trichomonal
  • vaginitis, positive bimanual exam consistent with pelvic inflammatory disease).
  • 9. Any clinically significant immune suppressing condition.
  • 10. Participants with a significant acute condition or any other condition that in the opinion of the
  • Investigator might interfere with the evaluation of the study objectives.
  • 11. Currently taking any of the following medications: over the counter (OTC) intra-vaginal
  • preparation, or any prescription that in the opinion of the Investigator could interfere with the
  • interpretation of the results, within 2 weeks of enrollment.
  • 12. Hypersensitivity to any component of other nucleoside analogues (such as cidofovir, etc.).
  • 13. Participation in any clinical study with an experimental medication or device within 30 days
  • or 5 half-lives (whichever is longer) of enrollment.
  • 14. Menses expected to start within 7 days of enrollment.
  • 15. Current alcohol or substance abuse as assessed by the Principal Investigator.

研究者

发起方
Antiva Bioscience, Inc.

相似试验